This article is more than 5 years old. Information may no longer be current.
Baseline JAK phosphorylation associated with 1-year treatment response in RA
The baseline Janus kinase phosphorylation profile in peripheral blood leukocytes was associated with 1-year treatment response in patients with early rheumatoid arthritis, according to recently published data.
Krista Kuuliala, PhD, at Helsinki University Hospital and the University of Helsinki, and colleagues assessed 35 disease-modifying antirheumatic drug (DMARD)-treatment naive patients with early rheumatoid arthritis (RA) who provided blood samples for whole blood flow cytometric phosphorylation of Janus kinases (JAKs) in CD4+ and CD8+ T cells, CD19+ B cells and CD14+ monocytes. Researchers determined treatment response after 1 year of treatment with synthetic DMARDs and they defined remission as absence of tender and swollen joints and normal erythrocyte sedimentation rate.
Researchers found high JAK3 phosphorylation in CD4+ and CD8+ T cells, CD19+ B cells and CD14+ monocytes and low JAK2 phosphorylation in CD14+ monocytes were associated with remission after treatment with synthetic DMARDs. – by Will Offit
Disclosures: The researchers report support by the Paulo Foundation and Finnish Cultural Foundation and by the Helsinki University Central Hospital Research Funds and Finska Läkaresälskapet.